Evelo Biosciences and Mayo Clinic this week entered a collaborative
agreement regarding immuno-microbiome-based cancer therapies.
"This collaboration supports Mayo Clinic's commitment to world-leading science and the work of our investigators as we explore the cancer microbiome," Mayo Clinic Professor of Obstetrics and Gynecology Dr. Andrea Mariani said. "We look forward to working with Evelo and on behalf of patients everywhere who may ultimately benefit from our activities."
Evelo researchers will work with the Mayo Clinic investigators to examine patient stool samples and tumor biopsies. The materials will be analyzed to isolate cancer-associated bacteria. The results will be added to Evelo's cancer-associated bacteria library and used to develop potential onco-microbials as cancer therapies.
Targeting specific types of bacteria associated with cancer development and suppression can lead to personalized treatments. Evelo will research and suggest bacteria that stimulate an immune system response against the cancer cells. Current Evelo research has suggested several candidates for treatment, which may be advance to clinical trials next year.
"We are excited to work with Mayo Clinic, a world leader in cancer research," Evelo's Head of Scientific Strategy Dr. Brian Goodman said. "Understanding how certain cancer-associated bacteria disrupt tumors is an important step toward developing new medicines for cancer."